Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy

Recruiting now

Conditions studied: Nephropathy, Opportunistic Viral Infection, Polyoma Virus Nephropathy, BK Nephropathy, BK Viremia; BKV DNAemia, BK Virus Infection, BK Polyomavirus, Immune Response, Neutralizing Antibodies

In brief

The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients. Although BKV reactivation after transplantation is well established, the origin of the replicating virus remains uncertain. Current evidence suggests that BKV detected in recipients may originate either from the transplanted kidney (donor-derived) or from viral reactivation in the recipient. The evaluation of new biomarkers to predict BKV replication are needed. This study seeks to address the following key questions: * Origin of the replicating virus: Is the BKV detected in the recipient identical to the virus originating from the donor kidney? * Host immune response and viral genotype: Is there an association between the recipient's immune response and the genotype of the replicating BKV? * Differences in immune response according to viral replication profile: Does the immune response differ between patients presenting isolated BKV viruria and those with both viruria and viremia? * Can new biomarkers help predict BKV replication and viremia? Patients will be grouped according to their BKV replication profile: Group 1: patients with BKV viruria without viremia Group 2: patients with both BKV viruria and viremia Comparisons between these two groups will help identify whether different viral genotypes or immune responses are associated with systemic dissemination (viremia). Kidney transplant recipients will be included if they present BKV viruria during their post-transplant follow-up. Additional blood samples will be collected during scheduled follow-up visits at the university hospital. These visits are part of routine clinical care, and no extra visits will be required specifically for the study.

Key facts

Study ID

NCT07347769

Run by

University Hospital, Grenoble

People needed

100

Starts

2026-03-11

Expected to finish

2030-09-11

Last updated by the study team

2026-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant patients with a first positive BK virus viral load in urine. - BK virus viral load in urine > 3 log copies/mL.
• More than 3 months post-transplant and less than 2 years post-transplant.
• Men or women aged 18 years and older.
• Followed up at Grenoble Alpes University Hospital.
• Affiliated with social security or beneficiary of such a scheme.
• Patients who are not opposed to the TYPIK study.

You may not qualify if…

• Expected renal graft survival is < 6 months, estimated by an eGFR < 15 mL/min/1.73 m² at the time of BKPyV viruria
• Patients who object to the use of their data and/or samples for research purposes
• Subjects who are excluded from another study
• Subjects under administrative or judicial supervision

Where it is running

• CHUGA — Grenoble, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.